MAPT and Cognitive impairment: Our study has shown that bezafibrate exerts considerable and long-lasting protective effects on cognitive impairment, neuronal loss, tau pathology, cerebral glucose hypometabolism, and neuroinflammation induced by STZ-ICV administration.